SynthesisPhysiological reports2025
Assessing the therapeutic potential of vagus nerve stimulation in autoimmune diseases: A systematic review.
Synthesis in Physiological reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing the therapeutic potential of vagus nerve stimulation in autoimmune diseases: A systematic review.Physiological reports · 2025Pooled it
- Sacral nerve stimulation modulates disease activity and autonomic function in active rheumatoid arthritis: a randomized pilot study.Clinical rheumatology · 2026Trial
- Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2026Review
- Effects of herbal medicines and their phytoconstituents on vagus nerve stimulation: a systematic review ofFrontiers in pharmacology · 2026Review
- Vagus nerve stimulation: a novel approach for refractory rheumatoid arthritis.Clinical rheumatology · 2026Article
- The Role of Gut Microbiota in Modulating Immune Signaling Pathways in Autoimmune Diseases.Neuromolecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence suggests that the vagus nerve can modulate the immune system in experimental settings. Vagus nerve stimulation (VNS), initially developed for managing epilepsy, is now being explored as a treatment for autoimmune diseases due to its potential immunomodulatory effects. This systematic review evaluates the therapeutic potential of VNS in autoimmune diseases by critically appraising findings from human clinical studies. This systematic review was conducted in accordance with the PRISMA guideline, with a comprehensive literature search performed in Ovid, Cochrane, and PubMed databases up to July 2024. Studies focusing on VNS in patients with autoimmune diseases were eligible, and the quality of study was assessed using the QualSyst tool. Of the 53 papers identified for full-text assessment, 19 studies met the eligibility criteria. Findings suggest that VNS is a promising adjunctive therapy for Crohn's disease and rheumatoid arthritis, showing potential to alleviate symptoms and modulate immune responses. The efficacy and safety of VNS vary widely across studies, highlighting the complex nature of autoimmune diseases and the diverse mechanisms of VNS action. Future research should prioritize large-scale, randomized controlled trials with standardized protocols to further elucidate the efficacy, long-term safety, and optimal parameters of VNS across various autoimmune conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.